Basel alliance seeks to combat antibiotic resistance
The Spearhead alliance has been founded in Basel with the aim of combating the silent pandemic of antimicrobial resistance. By 2050, this will cause around four times as many deaths as the coronavirus pandemic in 2020. The alliance is seeking to create a globally scalable digital platform for the use of antibiotics.
A new alliance will seek to combat the silent pandemic of antimicrobial resistance (AMR) using digital measures. It has now been founded in Basel with the support of Innosuisse, the Swiss Innovation Agency, and is known as the Swiss Pandemic & AMR – Health Economy Awareness Detect (SPEARHEAD). The consortium includes eight institutional and four private partners, most of whom are based in the Basel Area: the University of Basel, the University Children’s Hospital Basel (UKBB), Novartis, Resistell AG and Waat Switzerland GmbH.
Moreover, the Institute for Design at the University of Applied Sciences and Arts of Southern Switzerland (SUPSI), the Dalle Molle Institute for Artificial Intelligence (IDSIA) at SUPSI, two of Switzerland’s five university hospitals and the reinsurance firm Swiss Re also form part of the SPEARHEAD alliance. As detailed in a joint press release, the partners intend to play their part in a rapid digital pandemic fight by calling on their expertise in relation to Covid-19 and AMR. After all, AMR is expected to cause around 10 million deaths in the year 2050, which would represent a fourfold increase on the death level attributable to the coronavirus pandemic year 2020. As part of this, Basel will be positioned as an important location in combatting antibiotic resistance.
Five main goals
The project will seek to develop a digital platform that has five main goals: establishing the flow of data to and from decision-makers in real time, making better use of Big Data for risk stratification and enabling real-time diagnostics to render centralized laboratory infrastructure superfluous. In addition, the population and municipalities should be more involved, while finally, the financial impact of the innovations presented should also be taken into account at an early stage
SPEARHEAD is the first cooperation within the framework of the Bio-Campus, a strategic tri-national (Switzerland, France and Germany) initiative established by the University of Basel. Its vision is focused on innovatively shaping the global future of healthcare and wellbeing together with partners from the worlds of science, industry and civil society in addition to startups.
Share this article
You may also be interested in
Evolva launches new line for manufacturers of personal care products
Evolva, a manufacturer of active ingredients based in Reinach in the canton of Basel-Landschaft, will be presenting its new product...Read More
Record figure for startups in the Basel Area
Basel Area Business & Innovation has supported a record number of 96 company startups in 2022. The number of settlements...Read More
Noema Pharma raises 103 million Swiss francs from investors
Noema Pharma has raised a total of 103 million Swiss francs as part of an oversubscribed Series B financing round....Read More
Why CDMO companies choose the Basel Area as their location
Originally, this article was published by the US magazine Outsourced Pharma under the title "Why Location Matters". The article highlights...Read More
Basel still the most attractive small city for business in Europe
As with last year, Basel once again features among the most attractive locations in Europe for investments. It was ranked...Read More
Ariceum Therapeutics establishes subsidiary in Basel
The German life sciences firm Ariceum Therapeutics has established a subsidiary in Basel. This company has received support from Basel...Read More